Capricor Therapeutics (CAPR) Accumulated Expenses (2010 - 2026)

Capricor Therapeutics' Accumulated Expenses history runs 11 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 10.34% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 10.34% YoY), while the FY2025 annual figure was $15.6 million, up 509.5% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.8 million, down from $15.6 million in the prior quarter.
• The five-year high for Accumulated Expenses was $15.6 million in Q4 2025, with the low at $2.6 million in Q4 2024.
• The 3-year median for Accumulated Expenses is $4.2 million (2025), against an average of $6.7 million.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses soared 509.5% in 2025, then dropped 10.34% in 2026.
• Capricor Therapeutics' Accumulated Expenses stood at $2.6 million in 2024, then jumped by 509.5% to $15.6 million in 2025, then slumped by 75.56% to $3.8 million in 2026.
• Business Quant data shows CAPR's Accumulated Expenses at $3.8 million in Q1 2026, $15.6 million in Q4 2025, and $9.9 million in Q3 2025.